What is Mekonos?
Founded in 2017 and headquartered in California, Mekonos operates at the vanguard of biotechnology. The company specializes in developing advanced delivery systems that enable precise, scalable, and cost-effective manipulation of cells. By integrating micro-electromechanical systems with synthetic biology, Mekonos provides a unique platform that facilitates the development of next-generation personalized medicines. This technological edge allows the firm to overcome traditional bottlenecks in cell engineering, positioning it as a critical player in the global biotech ecosystem. The company's focus on high-precision delivery is essential for the future of curative treatments, where accuracy and efficiency are paramount for clinical success.
How much funding has Mekonos raised?
Mekonos has raised a total of $29.6M across 2 funding rounds:
Unspecified
$4.6M
Series A
$25M
Unspecified (2020): $4.6M with participation from Elementum Ventures, HikeVentures, Novartis AG, CRCM Ventures, and Good AI Capital
Series A (2021): $25M led by PEAK6 Strategic Capital,, Fiscus Ventures, and Reimagined Ventures
Key Investors in Mekonos
Reimagined Ventures
Reimagined Ventures is a venture capital firm that invests in visionary entrepreneurs across various industries, providing unparalleled flexibility of capital to support innovative ideas that address persistent challenges.
CRCM Ventures
CRCM L.P. is a registered investment adviser based in San Francisco, focusing on tailored financial strategies and professional investment management for individuals and institutions.
Good AI Capital
Good AI Capital is an investment firm dedicated to harnessing the power of artificial intelligence to address significant global challenges, focusing on sectors such as Healthcare, Enterprise, and Automation.
What's next for Mekonos?
Looking ahead, the recent capital influx will likely be directed toward scaling manufacturing capabilities and expanding clinical partnerships. As Mekonos moves deeper into the enterprise-level phase of its lifecycle, the focus will shift toward optimizing its platform for commercial-scale production and securing regulatory milestones. The strategic backing from a diverse group of investors provides not only the necessary financial runway but also the operational expertise required to navigate the rigorous demands of the healthcare sector. Future growth will likely be defined by the successful deployment of its technology in high-impact therapeutic areas, further cementing its role as a leader in the synthetic biology market.
See full Mekonos company page
